^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK inhibitor

    Related drugs:
    1d
    Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition. (PubMed, Mol Ther Oncol)
    Importantly, co-administration of ruxolitinib, a clinically approved JAK1/2 inhibitor, dampened IFN-β signaling and rescued mice from lethal toxicity. Collectively, these findings define the pathophysiological consequences of sustained systemic IFN-β exposure and identify ruxolitinib as a potential mitigation strategy to manage IFN-β-mediated toxicity during OV treatment.
    Journal • IO biomarker
    |
    IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2) • IFNB1 (Interferon Beta 1)
    |
    Jakafi (ruxolitinib)
    7d
    Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib. (clinicaltrials.gov)
    P=N/A, N=20, Completed, Benha University
    New trial
    |
    IL15 (Interleukin 15)
    9d
    JADORE-BARI: Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica (clinicaltrials.gov)
    P3, N=140, Recruiting, University Hospital, Brest | Not yet recruiting --> Recruiting
    Enrollment open
    11d
    JAKUVEITE: Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (clinicaltrials.gov)
    P3, N=33, Not yet recruiting, University Hospital, Rouen | Trial completion date: Aug 2029 --> Dec 2029 | Trial primary completion date: Aug 2029 --> Dec 2029
    Trial completion date • Trial primary completion date
    15d
    Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo (clinicaltrials.gov)
    P2, N=156, Completed, Minghui Pharmaceutical (Hangzhou) Ltd | Active, not recruiting --> Completed
    Trial completion
    15d
    A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) (clinicaltrials.gov)
    P1/2, N=13, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed --> Terminated; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
    Trial termination
    |
    Anxu (rovadicitinib)
    16d
    JAKCNIASSILD: A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, China-Japan Friendship Hospital | Not yet recruiting --> Recruiting | Initiation date: Feb 2026 --> May 2026
    Enrollment open • Trial initiation date
    |
    methylprednisolone sodium succinate
    16d
    ODEN: Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden (clinicaltrials.gov)
    P=N/A, N=102, Completed, Pfizer | Recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Mar 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    tofacitinib
    16d
    TQ05105-I-01: A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1, N=79, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown status --> Completed | N=50 --> 79
    Trial completion • Enrollment change
    |
    Anxu (rovadicitinib)
    17d
    BIRD: Baricitinib in Patients With Relapsing or naïve Dermatomyositis (clinicaltrials.gov)
    P3, N=62, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    17d
    TQ05105-Ⅱ-01: A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis (clinicaltrials.gov)
    P2, N=107, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    JAK2 (Janus kinase 2)
    |
    hydroxyurea • Anxu (rovadicitinib)
    19d
    CDAK539A12303: A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior treatment with a Janus kinase inhibitor. (2025-523555-66-00)
    P2/3, N=60, Not yet recruiting, Novartis Pharma AG
    New P2/3 trial
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)